Pfizer Inc. shares rose 3.01% as the stock reached a 20-day high, reflecting positive market conditions with the Nasdaq-100 up 0.86% and the S&P 500 up 0.47%.
The company's ongoing late-stage trials for its cancer drug PF-4404 are expected to secure approvals for multiple cancer types, which could significantly enhance its financial performance and help navigate upcoming patent expirations. Additionally, Pfizer's acquisition of the mid-stage asset MET-097i in the weight management market indicates a strategic diversification that is crucial for future growth.
These developments suggest that Pfizer is positioning itself well to overcome challenges posed by patent expirations, and the market's optimism about its drug pipeline could lead to further stock appreciation in the coming months.
Wall Street analysts forecast PFE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PFE is 28.56 USD with a low forecast of 24.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Analyst Rating
Wall Street analysts forecast PFE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PFE is 28.56 USD with a low forecast of 24.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
11 Hold
0 Sell
Moderate Buy
Current: 25.880
Low
24.00
Averages
28.56
High
35.00
Current: 25.880
Low
24.00
Averages
28.56
High
35.00
UBS
Neutral
initiated
$25
2026-01-06
Reason
UBS
Price Target
$25
AI Analysis
2026-01-06
initiated
Neutral
Reason
UBS assumed coverage of Pfizer with a Neutral rating and $25 price target. The firm noted a backdrop of continued revenue uncertainty with $15B-$20B in revenues from key drugs losing patient exclusivity over the coming roughly three years. Though the firm is positive on the recent MTSR obesity deal, Pfizer needs to do more to offset 2028 LOE risk, the analyst tells investors in a research note.
BofA
Jason Gerberry
Neutral
downgrade
$28 -> $27
2025-12-16
Reason
BofA
Jason Gerberry
Price Target
$28 -> $27
2025-12-16
downgrade
Neutral
Reason
BofA analyst Jason Gerberry lowered the firm's price target on Pfizer to $27 from $28 and keeps a Neutral rating on the shares after the company "notably called out" faster COVID-19 product erosion relative to prior guidance as part of its 2026 outlook call. The firm, which "modestly" reduced its 2026 Pfizer sales and EPS estimates and its FY27 EPS estimate following the guidance call, looks to planned obesity data updates from the Metsera acquisition to better understand the company's potential obesity differentiation.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for PFE
Unlock Now
BofA
Jason Gerberry
Neutral
downgrade
$29 -> $28
2025-12-15
Reason
BofA
Jason Gerberry
Price Target
$29 -> $28
2025-12-15
downgrade
Neutral
Reason
BofA analyst Jason Gerberry lowered the firm's price target on Pfizer to $28 from $29 and keeps a Neutral rating on the shares. The firm, which struggles to see a rerating catalyst as the company works through its multi-year loss of exclusivity period, is shifting its valuation basis to its FY27 EPS estimate.
Morgan Stanley
Equal Weight
downgrade
$32 -> $28
2025-12-12
Reason
Morgan Stanley
Price Target
$32 -> $28
2025-12-12
downgrade
Equal Weight
Reason
Morgan Stanley lowered the firm's price target on Pfizer to $28 from $32 and keeps an Equal Weight rating on the shares. The firm expects many of the policy overhangs that dominated the biopharma conversation this year to wane in 2026, bringing the focus back to fundamentals, the analyst tells investors in a 2026 outlook note for the group.
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
